时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
Evidence suggests that FZLSHYD can improve outcomes in prostate cancer and inhibit CT.36 However, the mechanism underlying its action remains unclear.
方法
It can also be transmitted through the birth canal, causing neonatal ocular conjunctivitis and pneumonia.3,4 Patients with untreated or failed treatments of CT infections may develop chronic infections, clinically defined as “persistent infections,” with chances of acute infection, not treated formally, progressing to persistent infection being as high as 89%.5 CT seriously affects the reproductive health and quality of life of patients.；Furthermore, inhibition of the PI3K/Akt/mTOR pathway was assessed for determining the effect of FZLSHYD on CT infection model mice to identify therapeutic avenues and targets for persistent CT infection.2Methods2.1Preparation of FZLSHYDHuangQi (30 g), NanShaShen (20 g), HongJingTian (10 g), YinHua (20 g), LianQiao (15 g), JieGeng (15 g), HongTeng (20 g), YiYiRen (20 g), JingJie (15 g), HuangQin (6 g), HuPoMo (3 g), ShengBieJia (9 g), and DanSheng (15 g) were decocted twice in eight-times the amount of water, for 2 h each time.；The extract was filtered through a 0.22 μm filter membrane, and 10 μL of the filtrate was analyzed using an Ultrahigh-Performance Liquid Chromatograph (LC-30, Shimadzu, Japan) coupled with a mass spectrometer (SCIEX 5600, AB SCIEX™, USA).
核心结论
These results indicated that FZLSHYD treatment inhibited CT infection-induced autophagy and activated the PI3K/Akt/mTOR pathway.Fig. 2Effects of FZLSHYD on autophagy and the PI3K/Akt/mTOR pathway in splenic CD8+T cells isolated from mice with genital tract CT infection (A) Transmission electron microscopy (Magnification: ×15000; Scale bar: 1 μm, n = 3, cell nucleus (N), mitochondria (Mi), rough endoplasmic reticulum (RER), blue arrow: autophagosomes, yellow arrow: expansion of rough endoplasmic reticulum).；In this study, we found that FZLSHYD attenuated uterine and fallopian tube tissue damage, inhibited CD8+ T cell autophagy, and activated the PI3K/Akt/mTOR signaling pathway.；However, it is necessary to further identify the main components of FZLSHYD involved in the treatment of CT infection.Persistent CT infection of the genital tract can cause pathological changes and complications in the upper genital tract, which is consistent with the lesions caused by CT in women.43 Therefore, improvement of the upper genital tract pathology should be considered as one of the treatment modalities in persistent CT infection of the reproductive tract.44 We found inflammatory cell infiltration in the uterine and fallopian tube tissues of CT-infected mice.
局限
However, the levels of p62, p-PI3K, p-Akt, and p-mTOR were significantly reduced.；Moreover, compared with the CT + MK2206 group, MK2206+FZLSHYD treatment decreased the autophagy of cells (Fig. 6A) and significantly decreased the levels of ATG5 and Beclin1, and the LC3-II/LC3-I ratio; however, the levels of p62, p-PI3K, p-Akt, and p-mTOR were significantly increased (p < 0.01, Fig. 6B).Fig. 5Effect of FZLSHYD on CD8+ T cells in the spleen of mice after CT infection of the genital tract after inhibition of the PI3K/Akt/mTOR pathway (A) Level of CD8+, CD8+OX40+, and CD8+LAG3+ in the spleen (n = 3).；However, FZLSHYD-H partially mitigates the enhanced effect of CT infection caused by the inhibition of the PI3K/Akt/mTOR pathway.4DiscussionNo effective treatment options are available for recurrent or persistent CT infections.35 FZLSHYD is a traditional Chinese medicinal formulation with TCM characteristics.
对本项目的价值
中高价值：属「营养感知—自噬—蛋白稳态轴」方向；mTOR / 自噬 / 蛋白质稳态栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.0/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 41,298 字符，题名指纹 0.94，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：PI3K/Akt/mTOR 通路在扶正利湿化瘀汤治疗持续性沙眼衣原体感染中的作用
- 英文标题：Role of PI3K/Akt/mTOR signaling in the therapeutic effects of Fuzheng Lishi Huayu Decoction on persistent Chlamydia trachomatis infection.
- 期刊与标识：Journal of traditional and complementary medicine · PMID 42979277 · DOI 10.1016/j.jtcme.2026.09.001 · PMC PMC13729022